Comment on: Butler et al. Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Gluca...

por Engel, Samuel S., Golm, Gregory T., Lauring, Brett
Publicado 2013

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

por Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.
Publicado 2013

Erratum to: Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

por Engel, Samuel S., Round, Elizabeth, Golm, Gregory T., Kaufman, Keith D., Goldstein, Barry J.
Publicado 2013

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

por Engel Samuel S, Golm Gregory T, Shapiro Deborah, Davies Michael J, Kaufman Keith D, Goldstein Barry J
Publicado 2013-01-01

Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis

por Engel, Samuel S, Golm, Gregory T, Shapiro, Deborah, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Publicado 2013

Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency

por Arjona Ferreira, Juan Camilo, Marre, Michel, Barzilai, Nir, Guo, Hua, Golm, Gregory T., Sisk, Christine McCrary, Kaufman, Keith D., Goldstein, Barry J.
Publicado 2013

A Randomized Clinical Trial to Evaluate the Efficacy and Safety of Co-Administration of Sitagliptin with Intensively Titrated Insulin Glargine

por Mathieu, Chantal, Shankar, R. Ravi, Lorber, Daniel, Umpierrez, Guillermo, Wu, Fan, Xu, Lei, Golm, Gregory T., Latham, Melanie, Kaufman, Keith D., Engel, Samuel S.
Publicado en Diabetes Ther (2015)

Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

por Miller, Sam, Krumins, Tania, Zhou, Haojin, Huyck, Susan, Johnson, Jeremy, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado en Diabetes Ther (2018)

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study

por Grunberger, George, Camp, Sarah, Johnson, Jeremy, Huyck, Susan, Terra, Steven G., Mancuso, James P., Jiang, Zhi Wei, Golm, Gregory, Engel, Samuel S., Lauring, Brett
Publicado en Diabetes Ther (2017)

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

por Williams-Herman, Debora, Engel, Samuel S, Round, Elizabeth, Johnson, Jeremy, Golm, Gregory T, Guo, Hua, Musser, Bret J, Davies, Michael J, Kaufman, Keith D, Goldstein, Barry J
Publicado 2010

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

por Hollander, Priscilla, Liu, Jie, Hill, Julie, Johnson, Jeremy, Jiang, Zhi Wei, Golm, Gregory, Huyck, Susan, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado en Diabetes Ther (2017)

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus

por Ji, Linong, Han, Ping, Wang, Xiaoyue, Liu, Jingdong, Zheng, Shaoxiong, Jou, Ying‐Ming, O'Neill, Edward A, Golm, Gregory T, Engel, Samuel S, Kaufman, Keith D, Shankar, R Ravi
Publicado en J Diabetes Investig (2016)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL r...

por Pratley, Richard E., Eldor, Roy, Raji, Annaswamy, Golm, Gregory, Huyck, Susan B., Qiu, Yanping, Sunga, Sheila, Johnson, Jeremy, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado en Diabetes Obes Metab (2018)

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐cont...

por Dagogo‐Jack, Samuel, Liu, Jie, Eldor, Roy, Amorin, Guillermo, Johnson, Jeremy, Hille, Darcy, Liao, Yuqin, Huyck, Susan, Golm, Gregory, Terra, Steven G., Mancuso, James P., Engel, Samuel S., Lauring, Brett
Publicado en Diabetes Obes Metab (2017)

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin gl...

por Roussel, Ronan, Duran‐García, Santiago, Zhang, Yilong, Shah, Suneri, Darmiento, Carolyn, Shankar, R. Ravi, Golm, Gregory T., Lam, Raymond L. H., O'Neill, Edward A., Gantz, Ira, Kaufman, Keith D., Engel, Samuel S.
Publicado en Diabetes Obes Metab (2018)